{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T03:05:25Z","timestamp":1784430325643,"version":"3.55.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.canrad.2025.104715","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T01:58:10Z","timestamp":1755741490000},"page":"104715","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Role of radiotherapy in the management of bladder cancer: Recommendations of the Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique, 2025 update"],"prefix":"10.1016","volume":"29","author":[{"given":"Paul","family":"Sargos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5791-5468","authenticated-orcid":false,"given":"Louis-Marie","family":"Sauvage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Riou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7533-2988","authenticated-orcid":false,"given":"David","family":"Azria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Loos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-3801","authenticated-orcid":false,"given":"Christophe","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0045-6003","authenticated-orcid":false,"given":"Vincent","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5935-5218","authenticated-orcid":false,"given":"Igor","family":"Latorzeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2094-1708","authenticated-orcid":false,"given":"St\u00e9phane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.canrad.2025.104715_bib0565","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.critrevonc.2015.04.006","article-title":"Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: a systematic review of clinical trials","volume":"95","author":"Arcangeli","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"10.1016\/j.canrad.2025.104715_bib0570","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.canrad.2025.104715_bib0575","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.canrad.2025.104715_bib0580","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/jnci\/djq121","article-title":"Use of radical cystectomy for patients with invasive bladder cancer","volume":"102","author":"Gore","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.canrad.2025.104715_bib0585","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2008.07.031","article-title":"Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology","volume":"55","author":"Shabsigh","year":"2009","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.canrad.2025.104715_bib0590","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.canrad.2025.104715_bib0595","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"issue":"34","key":"10.1016\/j.canrad.2025.104715_bib0600","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.canrad.2025.104715_bib0605","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1200\/JCO.23.00725","article-title":"Bladder-sparing treatment with radical dose radiotherapy is an effective alternative to radical cystectomy in patients with clinically node-positive nonmetastatic bladder cancer","volume":"41","author":"Swinton","year":"2023","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.canrad.2025.104715_bib0610","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1200\/JCO.2008.19.5776","article-title":"Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06","volume":"27","author":"Efstathiou","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104715_bib0615","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijrobp.2009.10.038","article-title":"Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (G\u00e9tug 97-015)","volume":"79","author":"Lagrange","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.canrad.2025.104715_bib0620","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2019.11.001","article-title":"Patient-reported quality of life outcomes in patients treated for muscle-invasive bladder cancer with radiotherapy\u00b1chemotherapy in the BC2001 phase III randomised controlled trial","volume":"77","author":"Huddart","year":"2020","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.canrad.2025.104715_bib0625","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.clon.2021.03.016","article-title":"Patient-reported outcomes and health-related quality of life following radiotherapy for bladder cancer","volume":"33","author":"Appleyard","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"2","key":"10.1016\/j.canrad.2025.104715_bib0630","doi-asserted-by":"crossref","first-page":"e6972","DOI":"10.1002\/cam4.6972","article-title":"Comparative survival analysis of bladder preservation therapy versus radical cystectomy in muscle-invasive bladder cancer","volume":"13","author":"Kang","year":"2024","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.canrad.2025.104715_bib0635","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijrobp.2023.07.027","article-title":"Disease-free survival of patients with muscle-invasive bladder cancer treated with radical cystectomy versus bladder-preserving therapy: a nationwide study","volume":"118","author":"Br\u00fcck","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.canrad.2025.104715_bib0960","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.prro.2022.05.014","article-title":"International consensus guidelines for adjuvant radiation therapy for bladder cancer after radical cystectomy: update from an IBIS workgroup","volume":"12","author":"Verghote","year":"2022","journal-title":"Pract Radiat Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104715_bib0640","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.canrad.2025.104715_bib0645","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.radonc.2021.06.011","article-title":"Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder","volume":"161","author":"Khalifa","year":"2021","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104715_bib0650","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semradonc.2022.10.005","article-title":"Multidisciplinary management and radiotherapy recommendations for clinically and pathologically node-positive bladder cancer","volume":"33","author":"Venkatesulu","year":"2023","journal-title":"Semin Radiat Oncol"},{"issue":"11","key":"10.1016\/j.canrad.2025.104715_bib0655","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.1998.16.11.3576","article-title":"Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03","volume":"16","author":"Shipley","year":"1998","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.canrad.2025.104715_bib0660","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1634\/theoncologist.5-6-471","volume":"5","author":"Kaufman","year":"2000","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.canrad.2025.104715_bib0665","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0360-3016(03)00718-1","article-title":"RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy","volume":"57","author":"Hagan","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.canrad.2025.104715_bib0670","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.urology.2008.09.036","article-title":"Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy","volume":"73","author":"Kaufman","year":"2009","journal-title":"Urology"},{"issue":"9","key":"10.1016\/j.canrad.2025.104715_bib0675","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(13)70255-9","volume":"14","author":"Mitin","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104715_bib0680","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ijrobp.2016.12.018","volume":"97","author":"Michaelson","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.canrad.2025.104715_bib0685","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.18.00537","article-title":"Bladder preservation with twice-a-day radiation plus fluorouracil\/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG\/RTOG 0712-a randomized phase II trial","volume":"37","author":"Coen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104715_bib0690","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0022-5347(01)62379-6","article-title":"A phase I\/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer","volume":"160","author":"Zietman","year":"1998","journal-title":"J Urol"},{"issue":"16","key":"10.1016\/j.canrad.2025.104715_bib0695","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.canrad.2025.104715_bib0700","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001 trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104715_bib0705","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.radonc.2006.09.001","article-title":"Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential phase II studies from the Trans Tasman Radiation Oncology Group","volume":"81","author":"Gogna","year":"2006","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104715_bib0710","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/0360-3016(93)90306-G","article-title":"Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12","volume":"25","author":"Tester","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.canrad.2025.104715_bib0715","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.1996.14.11.2901","article-title":"Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Coppin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104715_bib0720","doi-asserted-by":"crossref","first-page":"104557","DOI":"10.1016\/j.critrevonc.2024.104557","article-title":"Concomitant chemotherapy in trimodal treatment of patients with muscle invasive bladder cancer: a systematic review of prospective trials","volume":"205","author":"Baudelin","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"10.1016\/j.canrad.2025.104715_bib0725","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1200\/JCO.1993.11.11.2150","article-title":"Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study","volume":"11","author":"Housset","year":"1993","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104715_bib0730","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.radonc.2016.09.006","article-title":"Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: a pooled individual data analysis of eight phase I-II trials","volume":"121","author":"Caffo","year":"2016","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104715_bib0735","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ijrobp.2016.11.040","article-title":"Tolerability of concurrent chemoradiation therapy with gemcitabine (GemX), with and without prior neoadjuvant chemotherapy, in muscle invasive bladder cancer","volume":"97","author":"Thompson","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.canrad.2025.104715_bib0740","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ijrobp.2013.11.016","article-title":"Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long-term results of a phase 1 trial","volume":"88","author":"Azria","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.canrad.2025.104715_bib0745","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/cncr.25667","article-title":"Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: long-term cumulative results of 2 prospective single-institution studies","volume":"117","author":"Caffo","year":"2011","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.canrad.2025.104715_bib0750","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.euo.2024.01.014","article-title":"Benefit of neoadjuvant cisplatin-based chemotherapy for invasive bladder cancer patients treated with radiation-based therapy in a real-world setting: an inverse probability treatment weighted analysis","volume":"7","author":"Kool","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"10.1016\/j.canrad.2025.104715_bib0755","doi-asserted-by":"crossref","first-page":"786.e1","DOI":"10.1016\/j.urolonc.2021.03.009","article-title":"Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer","volume":"39","author":"Rodrigues Pessoa","year":"2021","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.canrad.2025.104715_bib0760","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.clgc.2023.07.011","article-title":"Does chemo-radiotherapy improve survival outcomes vs. radiotherapy alone for high-grade cT1 urothelial carcinoma of the bladder?","volume":"21","author":"Andruska","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"34","key":"10.1016\/j.canrad.2025.104715_bib0765","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.23.02510","article-title":"Bladder-preserving trimodality treatment for high-grade T1 bladder cancer: results from phase II protocol NRG Oncology\/RTOG 0926","volume":"42","author":"Dahl","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104715_bib0770","doi-asserted-by":"crossref","first-page":"702","DOI":"10.21037\/tau.2016.08.18","article-title":"Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?","volume":"5","author":"Sargos","year":"2016","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.canrad.2025.104715_bib0775","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ctrv.2018.07.011","article-title":"Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: a systematic-review and framework for adjuvant radiotherapy","volume":"70","author":"Sargos","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.canrad.2025.104715_bib0780","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.canrad.2016.08.131","article-title":"[Adjuvant radiotherapy for bladder cancer in patients with risk of locoregional recurrence: Who, what and how?]","volume":"21","author":"Sargos","year":"2017","journal-title":"Cancer Radiother"},{"issue":"5","key":"10.1016\/j.canrad.2025.104715_bib0785","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.euf.2021.11.004","article-title":"Adjuvant radiotherapy after radical cystectomy for patients with high-risk muscle-invasive bladder cancer: results of a multicentric phase II trial","volume":"8","author":"Fonteyne","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.canrad.2025.104715_bib0790","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijrobp.2016.04.032","article-title":"Development and validation of consensus contouring guidelines for adjuvant radiation therapy for bladder cancer after radical cystectomy","volume":"96","author":"Baumann","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.canrad.2025.104715_bib0795","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.purol.2020.12.003","article-title":"[Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer]","volume":"31","author":"Pignot","year":"2021","journal-title":"Prog Urol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104715_bib0800","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ijrobp.2024.09.040","article-title":"Bladder adjuvant radiation therapy (BART): acute and late toxicity from a phase III multicenter randomized controlled trial","volume":"121","author":"Murthy","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.canrad.2025.104715_bib0805","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.clgc.2018.09.008","article-title":"Development of a prediction tool for exclusive locoregional recurrence after radical cystectomy in patients with muscle-invasive bladder cancer","volume":"17","author":"Necchi","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.canrad.2025.104715_bib0810","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1748-717X-7-132","article-title":"Clinically significant bleeding in incurable cancer patients: effectiveness of hemostatic radiotherapy","volume":"7","author":"Cihoric","year":"2012","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104715_bib0815","first-page":"181","article-title":"Hypofractionated palliative radiotherapy for bladder cancer","volume":"24","author":"Dirix","year":"2016","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.canrad.2025.104715_bib0820","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/clon.1999.9075","article-title":"Hypofractionated radiotherapy for patients with carcinoma of the bladder","volume":"11","author":"Jose","year":"1999","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"10.1016\/j.canrad.2025.104715_bib0825","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1590\/S1677-5538.IBJU.2013.01.10","article-title":"Evaluation of acute toxicity and symptoms palliation in a hypofractionated weekly schedule of external radiotherapy for elderly patients with muscular invasive bladder cancer","volume":"39","author":"Kouloulias","year":"2013","journal-title":"Int Braz J Urol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104715_bib0830","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0167-8140(97)01943-9","article-title":"Hypofractionated radiotherapy for muscle invasive bladder cancer in the elderly","volume":"43","author":"McLaren","year":"1997","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104715_bib0835","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/0284186X.2021.1880025","article-title":"Palliative radiotherapy for bladder cancer: a systematic review and meta-analysis","volume":"60","author":"Tey","year":"2021","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104715_bib0840","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0360-3016(00)00430-2","article-title":"A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09","volume":"47","author":"Duchesne","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.canrad.2025.104715_bib0845","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canrad.2023.02.004","article-title":"The role of radiation therapy for de novo metastatic bladder and renal cancers","volume":"28","author":"Sargos","year":"2024","journal-title":"Cancer Radiother"},{"issue":"4","key":"10.1016\/j.canrad.2025.104715_bib0850","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3390\/cancers15041161","article-title":"Consolidative radiotherapy for metastatic urothelial bladder cancer patients with no progression and with no more than five residual metastatic lesions following first-line systemic therapy: a retrospective analysis","volume":"15","author":"Aboudaram","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.canrad.2025.104715_bib0855","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00345-023-04744-x","article-title":"Radiotherapy in metastatic bladder cancer","volume":"42","author":"Ashley","year":"2024","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104715_bib0860","first-page":"3009","article-title":"Pelvic chemoradiotherapy after chemotherapy for metastatic bladder cancer","volume":"13","author":"Passaperuma","year":"2006","journal-title":"Can J Urol"},{"issue":"29","key":"10.1016\/j.canrad.2025.104715_bib0865","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2016.66.7352","article-title":"Efficacy of high-intensity local treatment for metastatic urothelial carcinoma of the bladder: a propensity score-weighted analysis from the National Cancer Data Base","volume":"34","author":"Seisen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104715_bib0870","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.euo.2022.02.001","article-title":"Association between local radiation therapy to the primary bladder tumor and overall survival for patients with metastatic urothelial cancer receiving systemic chemotherapy","volume":"5","author":"Fischer-Valuck","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"12","key":"10.1016\/j.canrad.2025.104715_bib0875","first-page":"1417","article-title":"Randomized comparison of magnetic resonance imaging versus transurethral resection for staging new bladder cancers: results from the prospective BladderPath trial","volume":"43","author":"Bryan","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104715_bib0880","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijrobp.2003.10.039","article-title":"Impact of changes in bladder and rectal filling volume on organ motion and dose distribution of the bladder in radiotherapy for urinary bladder cancer","volume":"59","author":"Fokdal","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.canrad.2025.104715_bib0885","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13014-024-02484-9","article-title":"Adaptive radiotherapy for muscle invasive bladder cancer: a retrospective audit of two bladder filling protocols","volume":"19","author":"Guel","year":"2024","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104715_bib0890","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canrad.2020.08.046","article-title":"[A review of adaptive radiotherapy for bladder cancer]","volume":"25","author":"Cabaill\u00e9","year":"2021","journal-title":"Cancer Radiother"},{"issue":"6","key":"10.1016\/j.canrad.2025.104715_bib0895","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.urology.2005.07.006","article-title":"Risk assessment for occult malignancy in the prostate before radical cystectomy","volume":"66","author":"Kefer","year":"2005","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.canrad.2025.104715_bib0900","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.humpath.2006.01.027","article-title":"Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance","volume":"37","author":"Shen","year":"2006","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104715_bib0905","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.urology.2009.09.081","article-title":"Developing selection criteria for prostate-sparing cystectomy: a review of cystoprostatectomy specimens","volume":"75","author":"Richards","year":"2010","journal-title":"Urology"},{"issue":"2\u00a0Pt\u00a01","key":"10.1016\/j.canrad.2025.104715_bib0910","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0022-5347(01)69073-6","article-title":"Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder","volume":"167","author":"Nixon","year":"2002","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104715_bib0915","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000454736","article-title":"Impact of prostate involvement on outcomes in patients treated with radical cystoprostatectomy for bladder cancer","volume":"98","author":"Moschini","year":"2017","journal-title":"Urol Int"},{"issue":"2","key":"10.1016\/j.canrad.2025.104715_bib0920","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.radonc.2009.09.003","article-title":"Lipiodol injection for target volume delineation and image guidance during radiotherapy for bladder cancer","volume":"93","author":"Pos","year":"2009","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104715_bib0925","doi-asserted-by":"crossref","first-page":"e89754","DOI":"10.1371\/journal.pone.0089754","article-title":"Endoscopic gold fiducial marker placement into the bladder wall to optimize radiotherapy targeting for bladder-preserving management of muscle-invasive bladder cancer: feasibility and initial outcomes","volume":"9","author":"Garcia","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.canrad.2025.104715_bib0930","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3109\/0284186X.2015.1110250","article-title":"A review of the use of fiducial markers for image-guided bladder radiotherapy","volume":"55","author":"Nolan","year":"2016","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104715_bib0935","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13014-023-02338-w","article-title":"Clinical and dosimetric outcomes of image-guided, dose-painted radiotherapy in muscle invasive bladder cancer","volume":"18","author":"Navarro-Domenech","year":"2023","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104715_bib0940","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ijrobp.2013.11.211","article-title":"Occult pelvic lymph node involvement in bladder cancer: implications for definitive radiation","volume":"88","author":"Goldsmith","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.canrad.2025.104715_bib0945","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1016\/j.ijrobp.2011.05.051","article-title":"Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience","volume":"82","author":"Tunio","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.canrad.2025.104715_bib0950","doi-asserted-by":"crossref","first-page":"325.e15","DOI":"10.1016\/j.urolonc.2022.12.011","article-title":"Bladder only versus bladder plus pelvic lymph node chemoradiation for muscle-invasive bladder cancer","volume":"41","author":"Patel","year":"2023","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.canrad.2025.104715_bib0955","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.euo.2023.03.004","article-title":"Radiation-based therapy for muscle-invasive bladder cancer: contemporary outcomes across tertiary centers","volume":"6","author":"Kool","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104715_bib0965","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/j.ijrobp.2012.01.023","article-title":"Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas","volume":"83","author":"Gay","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1\u20132","key":"10.1016\/j.canrad.2025.104715_bib0970","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canrad.2021.11.001","article-title":"Organs at risk radiation dose constraints","volume":"26","author":"No\u00ebl","year":"2022","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2025.104715_bib0975","first-page":"1","article-title":"A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer","volume":"31","author":"Portner","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104715_bib0980","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","article-title":"Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials","volume":"22","author":"Choudhury","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104715_bib0985","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.ijrobp.2022.04.008","article-title":"Meta-analysis of elective pelvic nodal irradiation using moderate hypofractionation for high-risk prostate cancer","volume":"113","author":"Viani","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.canrad.2025.104715_bib0990","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1200\/JCO.1996.14.1.119","article-title":"Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802","volume":"14","author":"Tester","year":"1996","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104715_bib0995","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.meddos.2016.09.003","article-title":"Bladder radiotherapy treatment: a retrospective comparison of 3-dimensional conformal radiotherapy, intensity-modulated radiation therapy, and volumetric-modulated arc therapy plans","volume":"42","author":"Pasciuti","year":"2017","journal-title":"Med Dosim"},{"issue":"2","key":"10.1016\/j.canrad.2025.104715_bib1000","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clon.2019.07.017","article-title":"The Intensity-Modulated Pelvic Node and Bladder Radiotherapy (IMPART) trial: a phase II single-centre prospective study","volume":"32","author":"Tan","year":"2020","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.canrad.2025.104715_bib1005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13014-016-0618-6","article-title":"Clinical results of conformal versus intensity-modulated radiotherapy using a focal simultaneous boost for muscle-invasive bladder cancer in elderly or medically unfit patients","volume":"11","author":"Lutkenhaus","year":"2016","journal-title":"Radiat Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104715_bib1010","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s13566-019-00411-0","article-title":"Intensity-modulated radiotherapy is superior to three-dimensional conformal radiotherapy in the trimodality management of muscle-invasive bladder cancer with daily cone beam computed tomography optimization","volume":"8","author":"Sherry","year":"2019","journal-title":"J Radiat Oncol"},{"issue":"10","key":"10.1016\/j.canrad.2025.104715_bib1015","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3109\/0284186X.2014.928418","article-title":"A comparison of morbidity following conformal versus intensity-modulated radiotherapy for urinary bladder cancer","volume":"53","author":"S\u00f8ndergaard","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2025.104715_bib1020","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160667","article-title":"The future of image-guided radiotherapy will be MR guided","volume":"90","author":"Pollard","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.canrad.2025.104715_bib1025","doi-asserted-by":"crossref","first-page":"637591","DOI":"10.3389\/fonc.2021.637591","article-title":"MR-guided adaptive radiotherapy for bladder cancer","volume":"11","author":"Hijab","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2025.104715_bib1030","first-page":"27","article-title":"Feasibility of tumour-focused adaptive radiotherapy for bladder cancer on the MR-linac","volume":"35","author":"Mitchell","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104715_bib1035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.radonc.2022.03.014","article-title":"Online adaptive radiotherapy of urinary bladder cancer with full reoptimization to the anatomy of the day: initial experience and dosimetric benefits","volume":"171","author":"\u00c5str\u00f6m","year":"2022","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104715_bib1040","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ijrobp.2010.06.061","article-title":"Online adaptive radiotherapy for muscle-invasive bladder cancer: results of a pilot study","volume":"81","author":"Foroudi","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.canrad.2025.104715_bib1045","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1754-9485.2009.02066.x","article-title":"Offline adaptive radiotherapy for bladder cancer using cone beam computed tomography","volume":"53","author":"Foroudi","year":"2009","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"9","key":"10.1016\/j.canrad.2025.104715_bib1050","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.clon.2013.06.001","article-title":"Clinical implementation of adaptive hypofractionated bladder radiotherapy for improvement in normal tissue irradiation","volume":"25","author":"McDonald","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"6\u20137","key":"10.1016\/j.canrad.2025.104715_bib1055","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.canrad.2019.07.135","article-title":"[Adaptive radiotherapy: strategies and benefits depending on tumor localization]","volume":"23","author":"Briens","year":"2019","journal-title":"Cancer Radiother"},{"issue":"1","key":"10.1016\/j.canrad.2025.104715_bib1060","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.radonc.2011.01.027","article-title":"\u201cPlan of the day\u201d adaptive radiotherapy for bladder cancer using helical tomotherapy","volume":"99","author":"Murthy","year":"2011","journal-title":"Radiother Oncol"},{"issue":"9","key":"10.1016\/j.canrad.2025.104715_bib1065","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.clon.2019.06.005","article-title":"Adaptive radiotherapy for carcinoma of the urinary bladder: long-term outcomes with dose escalation","volume":"31","author":"Murthy","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.canrad.2025.104715_bib1070","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20120433","article-title":"Comparison of adaptive radiotherapy techniques for the treatment of bladder cancer","volume":"86","author":"Webster","year":"2013","journal-title":"Br J Radiol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104715_bib1075","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ijrobp.2006.07.013","article-title":"Online adaptive radiotherapy of the bladder: small bowel irradiated-volume reduction","volume":"66","author":"Burridge","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.canrad.2025.104715_bib1080","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.3109\/0284186X.2010.501813","article-title":"A comparison of three different adaptive strategies in image-guided radiotherapy of bladder cancer","volume":"49","author":"Vestergaard","year":"2010","journal-title":"Acta Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104715_bib1085","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jmir.2016.05.001","article-title":"Assessment of adaptive margins using a single planning computed tomography scan for bladder radiotherapy","volume":"47","author":"Canlas","year":"2016","journal-title":"J Med Imaging Radiat Sci"},{"issue":"2","key":"10.1016\/j.canrad.2025.104715_bib1090","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.meddos.2018.03.004","article-title":"Comparison of 3 image-guided adaptive strategies for bladder locoregional radiotherapy","volume":"44","author":"Kong","year":"2019","journal-title":"Med Dosim"},{"issue":"2","key":"10.1016\/j.canrad.2025.104715_bib1095","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.radonc.2011.04.008","article-title":"Patient-specific PTV margins in radiotherapy for bladder cancer\u00a0\u2013\u00a0a feasibility study using cone beam CT","volume":"99","author":"Tolan","year":"2011","journal-title":"Radiother Oncol"},{"issue":"6","key":"10.1016\/j.canrad.2025.104715_bib1100","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/j.clon.2021.02.012","article-title":"Advancing radiotherapy for bladder cancer: randomised phase II trial of adaptive image-guided standard or dose-escalated tumour boost radiotherapy (RAIDER)","volume":"33","author":"Hafeez","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"9","key":"10.1016\/j.canrad.2025.104715_bib1105","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.clon.2023.05.002","article-title":"Acute toxicity of hypofractionated and conventionally fractionated (chemo)radiotherapy regimens for bladder cancer: an exploratory analysis from the RAIDER trial","volume":"35","author":"Huddart","year":"2023","journal-title":"Clin Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104715_bib1110","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2024.09.006","article-title":"Dose-escalated adaptive radiotherapy for bladder cancer: results of the phase 2 RAIDER randomised controlled trial","volume":"87","author":"Huddart","year":"2025","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.canrad.2025.104715_bib1115","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN Guidelines\u00ae Insights: Bladder Cancer, Version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"issue":"3","key":"10.1016\/j.canrad.2025.104715_bib1120","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:59:42Z","timestamp":1765526382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321825001313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":112,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1278321825001313"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104715","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of radiotherapy in the management of bladder cancer: Recommendations of the Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique, 2025 update","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104715","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104715"}}